Cargando…
HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
Human leukocyte antigen-E (HLA-E) has been putatively associated with the pathogenesis of multiple myeloma (MM). Our study first showed that HLA-E was differentially expressed on MM and normal plasma cells (39.27 ± 27.01 and 11.28 ± 0.79, respectively). Based on the median value of HLA-E expression,...
Autores principales: | Yang, Ying, Liu, Zhuogang, Wang, Hongtao, Zhang, Guojun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219970/ https://www.ncbi.nlm.nih.gov/pubmed/34178656 http://dx.doi.org/10.3389/fonc.2021.670673 |
Ejemplares similares
-
Designing high affinity target-binding peptides to HLA-E: a key membrane antigen of multiple myeloma
por: Yang, Ying, et al.
Publicado: (2020) -
Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma
por: Yang, Ying, et al.
Publicado: (2020) -
Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014) -
Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets
por: Petrusca, Daniela N., et al.
Publicado: (2022) -
PIWI-Interacting RNA-004800 Is Regulated by S1P Receptor Signaling Pathway to Keep Myeloma Cell Survival
por: Ma, Huanxin, et al.
Publicado: (2020)